- Home
- WSHP vs SERA Comparison
WSHP vs SERA Comparison
Compare WSHP & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSHP | SERA |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | British Virgin Islands | United States |
| Employees | 20 | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 75.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | WSHP | SERA |
|---|---|---|
| Price | $5.50 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 48.5K | ★ 50.8K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $4.95 | $1.56 |
| 52 Week High | $250.00 | $4.09 |
Technical Indicators
Market Signals| Indicator | WSHP | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 43.26 |
| Support Level | $5.05 | $1.85 |
| Resistance Level | $7.50 | $2.03 |
| Average True Range (ATR) | 0.54 | 0.18 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 19.36 | 17.73 |
Price Performance
Historical ComparisonAbout WSHP WeShop Holdings Limited Class A Ordinary Shares
WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.